Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804794 | 0.90 | POLB (0.45) | USP1POLBPTGS2DDR1KCNH2 | |
| SCHEMBL15426413 | 0.84 | DDR1 (0.41) | POLBS1PR1DDR1 | |
| SCHEMBL16803689 | 0.82 | LMNA (0.35) | USP1POLBPTGS2CNR2LMNA | |
| SCHEMBL15426384 | 0.80 | RORC (0.37) | LMNADDR1BRD4 | |
| SCHEMBL16746510 | 0.79 | DDR1 (0.39) | POLBCNR2DDR1 | |
| SCHEMBL16803708 | 0.79 | POLB (0.38) | POLBBRD4 | |
| SCHEMBL16803686 | 0.79 | PDE10A (0.38) | POLBLMNASMN1; SMN2DDR1BRD4 | |
| SCHEMBL16604841 | 0.78 | BRD4 (0.34) | BRD4 | |
| SCHEMBL15412773 | 0.78 | BRD4 (0.40) | USP1BRD4 | |
| SCHEMBL15868290 | 0.78 | POLB (0.44) | POLBS1PR1DDR1BRD4EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364000-B2 | Method of controlling pests with fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150373982-A1 | METHOD OF CONTROLLING PESTS WITH FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150166573-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150373982-A1 | METHOD OF CONTROLLING PESTS WITH FUSED HETEROCYCLIC COMPOUND | NR4A1, NR2E1, NR0B1 | USP1 1355/4885POLB 4183/4885PTGS2 1853/4885 |
| US-20150166573-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, NR2E1, NR0B2 | USP1 1856/4885POLB 3690/4885PTGS2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.